by
Nicolae Done, PhD
Seminar date: 10/18/2017
Description: Clinical trials have shown superior effectiveness and non-inferior safety profiles for direct oral anticoagulants (DOACs) compared to warfarin in patients with nonvalvular atrial fibrillation. However, there is limited evidence from real-world clinical practice examining the long-term outcomes of DOAC therapy. VHA populations, in particular, may have different outcomes from clinical trial populations, given their greatly increased burden of physical illness, mental health conditions, and complicating socioeconomic challenges. This seminar will present preliminary data that compares the long-term effectiveness and safety of DOACs with warfarin using provider prescribing patterns as the instrumental variable. Intended audience: VA clinicians prescribing warfarin and DOACs, health services researchers interested in medication prescribing patterns, and economists interested in comparative effectiveness of pharmaceuticals using real-world evidence.
DOWNLOAD: PDF handout | Audio only (mp3) | transcript